AUTO1 for B-Lymphoblastic Leukemia and B-cell Non-Hodgkin Lymphoma
Contact
Description
The purpose of this study is to determine whether AUTO1, an experimental form of therapy, is safe and effective in helping the immune system fight cancer. AUTO1 uses immune cells, called T cells, that are collected from the blood using a process called leukapheresis and then modified in a lab to recognize and target cancer cells. These modified cells are then put back into the body through infusion.
Eligibility and criteria
What to expect
Participation in this study may last for up to 6 years and will involve the following procedures:
Receive lymphodepleting chemotherapy prior to infusion
Receive the study drug AUTO1
Have frequent clinic visits and monitoring
Have research blood samples drawn
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.